Kalvista Pharmaceuticals Inc (KALV)
EBITDA Growth
93.51%
Quarterly · Period ending:
KALV EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported93.51%period ending
Latest reported93.51%period ending
KALV Quarterly EBITDA YoY % (-261.77% → 93.51%)
Year-over-year change
High-resolution chart · PNG
KALV ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 93.511% | |
| 57.4033% | |
| -0.7088% | |
| -34.6752% | |
| -12.2597% | |
| -42.9201% | |
| -53.1381% | |
| -60.082% | |
| -70.1191% | |
| -36.5665% | |
| -24.3117% | |
| -9.7885% | |
| -9.0162% | |
| 5.4396% | |
| -13.1179% | |
| -43.2309% | |
| -33.823% | |
| -78.2445% | |
| -54.3564% | |
| -11.6102% | |
| -102.8096% | |
| -0.6107% | |
| -40.113% | |
| -53.842% | |
| 20.7488% | |
| -89.7972% | |
| -88.4551% | |
| -33.7117% | |
| -281.6998% | |
| -52.6304% | |
| 18.6757% | |
| -28.3711% | |
| 42.5025% | |
| 47.0088% | |
| -53,545,554.5455% | |
| -67,862.5% | |
| 22.258% | |
| -46.4415% | |
| 100.0002% | |
| 100.142% | |
| -33.1973% | |
| -33.8815% | |
| -34.3828% | |
| -121.5578% | |
| -154.5974% | |
| -261.7673% |